Adam Davenport
Chief Discovery Officer Proxygen GmbH
Adam Davenport is Proxygen’s Chief Discovery Officer. A seasoned drug hunter and innovator, he brings over 24 years of hands-on life science and partnership organization experience, having contributed to drug candidates and clinical assets through both governance and leadership roles. Prior to Proxygen, Adam’s outstanding career was spent at Dalriada Drug Discovery, as Chief R&D Officer guiding the oncology-focussed discovery collaborations and internal capability builds, and at Evotec, which he joined in 2000. Passionate about science and communication, Adam has authored over 60 patents, publications and external presentations and was co-recipient of the Bayer Healthcare Drug Discovery Award for Collaborative Innovation in 2017. Adam holds a B.Sc. Honours degree in Chemistry and a PhD in Organometallic Chemistry from the University of Leicester, UK.
Seminars
- Monovalent molecular glue degraders for histone acetyltransferase P300 (P300), a high-profile epigenetic target, were identified using Proxygen’s ligaseagnostic screening platform
- Molecular glue induces endogenous p300 degradation and modulates downstream signaling pathways recapitulating genetic dependencies in selected indications
- Ternary complex structural elucidation (Cryo-EM), Molecular Dynamics modeling, combined with biochemical and cellular characterization enabled rational drug design and optimization of preferential degradation of P300 over CREB-binding protein (CBP)
